Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity

Uridine triacetate: An orally administered, life-saving antidote for 5-FU overdose.

(2017) M. K. Bamat et al.   JOURNAL OF CLINICAL ONCOLOGY

Uridine triacetate for lethal 5-FU toxicity due to dihydropyrimidine dehydrogenase (DPD) deficiency.

(2017) R. von Borstel et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care

(2016) Didier Meulendijks et al.   EUROPEAN JOURNAL OF CANCER

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data

(2015) Didier Meulendijks et al.   LANCET ONCOLOGY

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

(2014) E. Bajetta et al.   ANNALS OF ONCOLOGY

P-0127 * CLINICAL EXPERIENCE WITH URIDINE TRIACETATE FOR 5-FLUOROURACIL OVEREXPOSURE: AN UPDATE

(2013) M. Bamat et al.   ANNALS OF ONCOLOGY

Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors

(2013) Anne Polk et al.   CANCER TREATMENT REVIEWS

5-fluorouracil induced cardiotoxicity: Review of the literature

(2013) Michael F. Sorrentino et al.   Cardiology Journal

Characteristics of medication errors with parenteral cytotoxic drugs

(2012) A. FYHR et al.   EUROPEAN JOURNAL OF CANCER CARE

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

(2012) Hans-Joachim Schmoll et al.   JOURNAL OF CLINICAL ONCOLOGY

5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases

(2011) Pierre-Yves Cordier et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Frequency of Uridine Monophosphate Synthase Gly213Ala Polymorphism in Caucasian Gastrointestinal Cancer Patients and Healthy Subjects, Investigated by Means of New, Rapid Genotyping Assays

(2011) Milena Gusella et al.   Genetic Testing and Molecular Biomarkers

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity

(2011) Ursula Amstutz et al.   PHARMACOGENOMICS

Enhanced Uridine Bioavailability Following Administration of a Triacetyluridine-Rich Nutritional Supplement

(2011) Melissa E. Weinberg et al.   PLoS One

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer

(2010) Michel Ducreux et al.   INTERNATIONAL JOURNAL OF CANCER

FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer

(2008) Saima Sharif et al.   CANCER INVESTIGATION

Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group

(2008) Matthias Schwab et al.   JOURNAL OF CLINICAL ONCOLOGY